ArticleTranslational lung cancer research2025
Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- From Method-Defined Signals to Reference Measurement Procedures: Two Decades of Mass Spectrometry-Based ProGRP Quantification.Journal of proteome research · 2026Article
- Article
- Elevated serum neuron-specific enolase as an indicator of poor chemo-immunotherapy outcomes and reduced CD8-positive lymphocyte infiltration in small-cell lung cancer: a retrospective cohort study.Translational lung cancer research · 2026Article
- Real-world effectiveness and safety of adebrelimab as first-line treatment in patients with extensive-stage small cell lung cancer.Translational lung cancer research · 2026Article
- Mutational Landscape and Treatment Response in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Real-World Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Anlotinib Plus Immune Checkpoint Inhibitors versus Chemotherapy in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer: A Real World, Exploratory Study.Drug design, development and therapy · 2026Article
- Spleen volume change as a prognostic and immunologic imaging biomarker in extensive-stage small-cell lung cancer receiving chemo-immunotherapy.Therapeutic advances in medical oncology · 2026Article
- The role of gut microbiota in liver metastasis of small cell lung cancer: mechanisms and therapeutic implications.Frontiers in cellular and infection microbiology · 2026Review
- Prognostic impact of baseline blood biomarkers in SCLC first-line treatment.Therapeutic advances in medical oncology · 2026Article
- Adebrelimab-based regimens as first-line treatment for ES-SCLC in specific populations: a real-world study in Chinese patients.Therapeutic advances in medical oncology · 2026Article
- MetaPredictomics: A Comprehensive Approach to Predict Postsurgical Non-Small Cell Lung Cancer Recurrence Using Clinicopathologic, Radiomics, and Organomics Data.Clinical nuclear medicine · 2025Article
- The Predictive Value of NLR, PLR, LMR, NPAR and D-Dimer on the Efficacy and Prognosis of First-Line Immunotherapy for Extensive-Stage Small Cell Lung Cancer.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemoimmunotherapy combining platinum-based chemotherapy and etoposide with an anti-programmed death-ligand 1 (PD-L1) antibody is the standard treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). However, the biomarkers that can predict outcomes after chemo-immunotherapy remain unclear. This study retrospectively investigated the prognostic factors after first-line chemoimmunotherapy in patients with ES-SCLC. Methods: This study included 110 patients with ES-SCLC who received chemoimmunotherapy as a first-line treatment. Clinical data were extracted from medical records, and inflammatory and nutritional factors such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutrition index (PNI), and advanced lung cancer inflammation index (ALI) were analyzed to determine the prognostic predictors. Survival data were analyzed using the log-rank test. Univariate and multivariate analyses of variables were performed using Cox regression. Results: The median patient age was 72 years (range, 50-88 years). At diagnosis, metastases were present in the brain, liver, and bones in 32.7%, 25.5%, and 39.1% of cases, respectively. The platinum-based chemotherapy regimens included atezolizumab in 67.3% of cases and durvalumab in 32.8%, respectively. Univariate analysis identified sex, ALI, pro-gastrin-releasing peptide (ProGRP), liver metastasis, and bone metastasis as significant predictors of progression-free survival (PFS), meanwhile, age, sex, performance status (PS), NLR, ALI, ProGRP, liver metastasis, and bone metastasis as significant predictors of overall survival (OS). Multivariate analysis identified liver metastasis as an independent predictor of PFS and OS. High ProGRP levels, bone metastasis, occurrence of immune-related adverse events (irAEs) of any grade, and partial response (PR) were significantly associated with the presence of liver metastasis. Multivariate analysis identified a combination of maximal tumor diameter >30 mm and the presence of >10 metastatic lesions as independent predictors of OS in 28 patients with liver metastasis. Conclusions: Liver metastasis is a significant predictor of outcomes after chemoimmunotherapy in patients with ES-SCLC. The maximal diameter and number of liver metastases may affect the immune response in patients with liver metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.